A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors.
about
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaborationBroad Antiviral Activity and Crystal Structure of HIV-1 Fusion Inhibitor SifuvirtideDifferential drug resistance acquisition in HIV-1 of subtypes B and CComparable long-term efficacy of Lopinavir/Ritonavir and similar drug-resistance profiles in different HIV-1 subtypesHIV-1 pol diversity among female bar and hotel workers in Northern TanzaniaTrends in Prevalence of HIV-1 Drug Resistance in a Public Clinic in Maputo, MozambiqueHIV-1 drug resistance and resistance testing.Overview of HIV molecular epidemiology among people who inject drugs in Europe and Asia.HIV-1 Genetic Variability and Clinical ImplicationsHIV-1 genetic variation and drug resistance development.Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure.Tribute to Mark WainbergE138A in HIV-1 reverse transcriptase is more common in subtype C than B: implications for rilpivirine use in resource-limited settings.The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors.Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir.Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor.HIV-1 antiretroviral resistance: scientific principles and clinical applicationsDistinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors.Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent.Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes.HIV diversity and drug resistance from plasma and non-plasma analytes in a large treatment programme in western Kenya.Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypesImpact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimenReplicative fitness costs of nonnucleoside reverse transcriptase inhibitor drug resistance mutations on HIV subtype C.Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors.High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens.Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs.HIV Genetic Diversity and Drug Resistance.Clinical management of HIV drug resistance.Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies.A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses.Drug resistance and viral tropism in HIV-1 subtype C-infected patients in KwaZulu-Natal, South Africa: implications for future treatment optionsPretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial.HIV-1 antiretroviral drug therapy.Cross-clade inhibition of recombinant human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus SIVcpz reverse transcriptases by RNA pseudoknot aptamers.New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir.Variability in the PR and RT genes of HIV-1 isolated from recently infected subjects.Antiviral activity and in vitro mutation development pathways of MK-6186, a novel nonnucleoside reverse transcriptase inhibitor
P2860
Q24792432-A433BD34-AF72-4E25-8F58-7A20D3763D15Q27676641-59F4938B-FC0B-4B1B-9CF8-4537A57B31D0Q28469273-636A0B21-1580-4200-82DE-A5F75E66A0FBQ28539169-03213A4F-0347-40B6-9FC5-C039B525ACB0Q28540536-4B27C05A-C34B-4498-A4ED-DE4B636CF3DBQ28546341-5FF61262-EB6A-4993-8F33-2FA03F438FC3Q30245693-7C9013CE-98D8-4BB9-A1F1-6E1B586B1679Q30249677-D645DBE9-F44E-48C8-B453-A1CF0A087F2CQ30352010-6C2041C3-3001-4641-932F-D3AEF80D9AB8Q30354857-8CC3693C-1C53-4A2A-9571-25866CB759D4Q33786428-22426D2C-5DBC-41E0-AEB0-02E338885EFFQ33846297-8A952A31-19E2-45A9-B711-E5321F9F1695Q33873990-E5D2C50E-A147-4668-A040-CCD6DE645B76Q34102246-C857B2B0-268A-46A1-BCA9-AB84E670C4A9Q34140913-E0B7B9EB-7206-400F-A9CE-ECEA1E3AD62DQ34189558-155F3867-6880-4F9C-ACB9-8802AD9B3EF9Q34280466-85BDE023-A7A0-43C9-A588-AD14EC6E1F5DQ34289973-1B76509A-E322-43DE-BD4E-4B55ADD59F30Q34303603-04DA401E-98E4-43F6-BB1C-600AF2269BADQ34352000-5066013E-7A49-4D8D-AC3B-88307296A47BQ34489239-BE45061D-B44F-433D-AD27-D29C3B64E7C7Q34529310-303B1F63-6A85-4682-BD6C-88E74AD6DD37Q34549498-3285D0BB-B887-4806-8FED-8D0F091FAB7AQ34563005-A15BEF80-812A-4E49-B8A0-0BA4A6FFF842Q34680647-3CD40C3B-AC22-4005-B512-AC2242BE3F30Q34933329-C63279E0-E433-4C73-B186-39E4C5DF7AEEQ35105844-9D7C925D-1A24-413D-B59C-861625CD680FQ35215399-AF59576E-9CAB-4F55-AE3F-33DF3D04B398Q35260403-EB9C03D1-4820-49C7-B6A5-2EF78AF49042Q35260590-5F04FD2C-1A8F-408F-A3B3-C17FB9E12E88Q35261045-FA742163-3128-4D13-BE3C-32C4A209F3E3Q35300021-27F689AA-B6C2-43FF-83EA-69AE9A6B933BQ35370552-002D103F-1FF2-46E9-B480-A6227711D939Q35386184-6C729BBD-828B-4A5F-ACAF-058C35E02455Q35588149-AFED0120-5CA8-4083-B0A6-BD574055EC0BQ35853012-E1C52717-7246-4BAF-B867-2C79142A81F2Q35857522-4FB213F9-DE90-40F3-9E75-319A0D1E257BQ35939695-BAEF3763-8211-4CC8-8DD4-E0B4FFCB26E9Q35944294-291C1C9C-5D52-4A2E-AB0A-6BE1B6E034F5Q36018893-422E3E40-59BC-4F3D-8D4C-8A8075903868
P2860
A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
A V106M mutation in HIV-1 clad ...... erse transcriptase inhibitors.
@en
A V106M mutation in HIV-1 clad ...... erse transcriptase inhibitors.
@nl
type
label
A V106M mutation in HIV-1 clad ...... erse transcriptase inhibitors.
@en
A V106M mutation in HIV-1 clad ...... erse transcriptase inhibitors.
@nl
prefLabel
A V106M mutation in HIV-1 clad ...... erse transcriptase inhibitors.
@en
A V106M mutation in HIV-1 clad ...... erse transcriptase inhibitors.
@nl
P2093
P1433
P1476
A V106M mutation in HIV-1 clad ...... erse transcriptase inhibitors.
@en
P2093
Bluma Brenner
Dan Turner
Daniela Moisi
Jonathan Schapiro
Mark A Wainberg
Maureen Oliveira
Mauricio Carobene
Mervi Detorio
Michel Roger
Richard G Marlink
P356
10.1097/00002030-200301030-00001
P407
P577
2003-01-01T00:00:00Z